CTXR NASDAQ
Citius Pharmaceuticals, Inc.
1W: +22.5%
1M: -6.8%
3M: -10.1%
YTD: -39.7%
1Y: -71.9%
3Y: -97.1%
5Y: -99.0%
$0.50
+0.05 (+11.62%)
Weekly Expected Move ±8.9%
$0
$0
$0
$0
$0
Credit Risk of going bust: higher than 92% of companies Debt: 34.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.05 (down 90%), Citius Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $7.2M against a stock market value of $13.8M.
Distance to default 1.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.7M (short-term plus half of long-term), stock volatility 109.7%; Altman Z'' -8.58. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.05 (down 90%), Citius Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $7.2M against a stock market value of $13.8M.
Distance to default 1.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $3.7M (short-term plus half of long-term), stock volatility 109.7%; Altman Z'' -8.58. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
15 relationships13
As Filer
counterparties named
2
As Counterparty
mentioned by others
4
Rel. Types
2021-09-07
Earliest Filing
2024-09-13
Latest Filing
acquirer: 6
partner: 3
target: 2
investor: 2
Counterparties (Filed by CTXR)
13 relationshipsCompanies named in CTXR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. | CTXR | acquirer | Parent company entering merger and shared services agreement | 2024-08-16 | View |
| Citius Oncology, Inc. | CTOR | target | Wholly owned subsidiary of Citius Pharma merged into TenX | 2024-08-16 | View |
| TenX Keane Acquisition | — | acquirer | Cayman Islands company acquiring Citius Oncology | 2024-08-16 | View |
| TenX Merger Sub, Inc. | — | acquirer | Delaware subsidiary of TenX used to merge with SpinCo | 2024-08-16 | View |
| 10XYZ Holdings LP | — | investor | Delaware limited partnership and shareholder of TenX | 2024-08-16 | View |
| Citius Pharmaceuticals, Inc. | CTXR | acquirer | Parent company entering merger agreement | 2023-10-24 | View |
| Citius Oncology, Inc. | CTOR | target | Wholly owned subsidiary of Citius Pharma being merged | 2023-10-24 | View |
| TenX Keane Acquisition | — | acquirer | Cayman Islands exempted company entering merger agreement | 2023-10-24 | View |
| TenX Merger Sub Inc. | — | acquirer | Delaware corporation and wholly owned subsidiary of TenX | 2023-10-24 | View |
| 10XYZ Holdings LP | — | investor | Sponsor entering support agreement | 2023-10-24 | View |
| Dr. Reddy's Laboratories SA | RDY | partner | Licensor of E7777 exclusive license rights | 2021-09-07 | View |
| Dr. Reddy's Laboratories, Ltd. | RDY | partner | Parent company of Dr. Reddy's Laboratories SA | 2021-09-07 | View |
| Eisai Co., Ltd. | — | partner | Original licensor of E7777 receiving milestone payments | 2021-09-07 | View |
Mentioned As Counterparty
2 mentionsOther companies that named CTXR in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-26 | Earnings Release; Exhibits | View | |
| 2026-08-21 | Delisting Notice | View | |
| 2026-08-14 | Earnings Release; Exhibits | View | |
| 2026-08-05 | Other Events; Exhibits | View | |
| 2026-06-01 | Other Events; Exhibits | View | |
| 2026-05-15 | Earnings Release; Exhibits | View | |
| 2026-05-08 | Material Agreement; Exhibits | Agreement | View |
| 2026-04-29 | Unregistered Equity Sales; Other Events; Exhibits | View | |
| 2026-04-24 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-04-06 | Shareholder Vote | View | |
| 2026-03-31 | Other Events; Exhibits | View | |
| 2026-03-10 | Other Events; Financial Statements and Exhibits | View | |
| 2026-03-04 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-13 | Results of Operations and Financial Condition; Notice of Delisting or Transfer; Financial Statements | View | |
| 2025-12-23 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-01 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-10-23 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-10-21 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-08 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR